Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
R Franco, OJ Schoneveld, A Pappa, MI Panayiotidis
Clinical evidence comes in tiers: mechanistic studies (does the molecule do what it should at the cellular level?), animal studies (does it produce the expected effect in a living organism?), and human trials (does it actually work on the people who will use it?)
A systematic review of 35 studies found consistent age-related GSH decline in blood and specific brain regions, including the precuneus, hippocampus, cingulate, and frontal cortex
Studies have shown that GLP-1 agonists can trigger effects in the brain, the heart, the liver, the pancreas, the stomach, and the musclesmeaning that they could have implications for conditions other than type 2 diabetes and obesity, such as heart disease, kidney disease, liver disease, and even neurological conditions such as Alzheimer's disease
